Triple-Negative Breast Cancer Latest Advances
Find the Latest Research About Triple-Negative Breast Cancer
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 4292 publications
Correction to "Losartan Enhances Radiosensitivity by Reversing Immunosuppressive Tumor Microenvironment Induced by Radiotherapy in TNBC".
Journal: Cancer science
Published: September 05, 2026
RIBOTAC-mediated degradation of hsa-microRNA-301a-3p suppresses TNBC bone metastasis.
Journal: Science advances
Published: August 26, 2026
Retraction notice to "TPTEP1 impedes the reprogramming of fatty acid metabolism in triple negative breast cancer via miR-1343-3p/SIRT3 axis" [Int. J. Biol. Macromol. 280 (2024) 135792].
Journal: International journal of biological macromolecules
Published: August 12, 2026
Molecular evaluation of residual disease following neoadjuvant chemotherapy in triple negative breast cancer CALGB40603 (Alliance).
Journal: The Journal of clinical investigation
Published: August 04, 2026
Nuclear translocation of phosphorylated YB-1 via small extracellular vesicles contributes to the malignant phenotype of triple negative breast cancer.
Journal: bioRxiv : the preprint server for biology
Published: July 29, 2026
Retraction notice to "LINC00668 silencing retards tumorigenesis via sponging miR-518c-3p to regulating WDR1 in triple negative breast cancer" [Int. J. Biol. Macromol. 282 (2024) 136698].
Journal: International journal of biological macromolecules
Published: July 22, 2026
Initial Evaluation of Dihydroartemisinin (DHA), Metformin and Taro Extract in Combination with Cisplatin for Enhanced Cytotoxicity in Triple-Negative Breast Cancer (TNBC) Cell Lines.
Journal: Journal of analytical oncology
Published: July 17, 2026
Corrigendum to "Ruyiping extract reduces lung metastasis in triple negative breast cancer by regulating macrophage polarization" [Biomed. Pharmacother. 141 (2021) 111883].
Journal: Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Published: July 02, 2026
Digitoxin as a novel synergistic partner of cisplatin in triple-negative breast cancer (TNBC) cells.
Digitoxin as a novel synergistic partner of cisplatin in triple-negative breast cancer (TNBC) cells.
Journal: Tumour biology : the journal of the International Society for Oncodevelopmental Biology and Medicine
Published: July 01, 2026
Selective Visualization of ROR1-Positive TNBC of the Mesenchymal-Like Subtype Using Peptide-Based 68Ga-PET Radiotracers.
Journal: Journal of medicinal chemistry
Published: June 29, 2026
A CXCR4/PD-L1 Bispecific Nanobody Engineered for Tumor Microenvironment Retention Mediates Sustained Synergy with Chemotherapy via Remodeling Immunity in TNBC.
Journal: Pharmaceuticals (Basel, Switzerland)
Published: June 23, 2026
Last Updated: 09/26/2026